SQI Diagnostics Appoints Paul Mountain to Board of Directors

    TORONTO, Aug. 9 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a
medical systems automation company focused on evolving laboratory-based
biomarker testing, today announced that Paul Mountain has been appointed to
its Board of Directors.
    "Paul brings a wealth of knowledge and experience in identifying,
developing, and integrating new technologies used in the automation of
clinical laboratory testing," said Eric Schneider, Chairman of the Board. "His
extensive industry knowledge and senior leadership experience will prove
invaluable as we prepare to commercialize our automated multiplex biomarker
    Mr. Mountain has significant clinical and diagnostic experience including
more than 25 years at MDS, Inc. culminating with the position of Senior Vice
President, Science and Technology. At MDS, Inc. he identified opportunities
and risks associated with new technologies and representing the company to the
external scientific and industrial community. Currently, he consults to
companies and institutions in the areas of organization, technology, and
strategy from a global perspective. He has a Bachelor of Science and a Master
of Science from St. Bonaventure University in New York and a Management
Curriculum from Penn State University. Mr. Mountain has long-term affiliations
with the Clinical Laboratory Management Association, where he served as
president, among other executive positions and committee memberships, and with
the Clinical and Laboratory Standards Institute where he served on numerous
committees and currently chairs the Area Committee on Automation and

    About SQI Diagnostics

    SQI Diagnostics is a medical systems automation company focused on
evolving laboratory-based biomarker testing. Using automation and proprietary
miniaturization technologies, SQI Diagnostics significantly improves the
economies of scale for laboratories performing multiple biomarker testing at
high volumes, allowing them to deliver patient results faster using less labor
and fewer resources. SQI Diagnostics' initial products target the $1.4 billion
autoimmune disease market, with initial products for Rheumatoid Arthritis and
Thrombosis scheduled for launch in 2007. SQI Diagnostics is based in Toronto,
Canada. For further information please visit www.sqidiagnostics.com.

    Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking

    This release was prepared by management of the Company who takes full
      responsibility for its contents. The TSX Venture Exchange has not
        reviewed and does not accept responsibility for the adequacy or
                       accuracy of this news release.

    %SEDAR: 00021000E

For further information:

For further information: Chief Financial Officer, Andrew Morris, (416)
674-9500 ext. 229, amorris@sqidiagnostics.com; Investor Relations, James
Smith, (416) 815-0700 ext. 229, jsmith@equicomgroup.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890